Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir with FTC-TDF for HIV NPEP
NCT02211690Phase 4Completed
- Start
- Aug 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir in human immunodeficiency virus infection (HIV). Primary endpoints: Number of participants with Adverse Events as a Measure of Safety and Tolerability at 12 weeks, Proportion of participants with NPEP failure at 12 weeks and 1 more. Started Aug 2014; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02211690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211690.